{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:54Z","timestamp":1792789674375,"version":"4.5.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["180642"],"award-info":[{"award-number":["180642"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Steven Diamond Professorship in Addiction Care Innovation"},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["Scholar Award"],"award-info":[{"award-number":["Scholar Award"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The overdose crisis in North America has prompted system-level efforts to restrict opioid prescribing for chronic pain. However, little is known about how discontinuing or tapering prescribed opioids for chronic pain shapes overdose risk, including possible differential effects among people with and without concurrent opioid use disorder (OUD). We examined associations between discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain, stratified by diagnosed OUD and prescribed opioid agonist therapy (OAT) status.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>For this retrospective cohort study, we used a 20% random sample of residents in the provincial health insurance client roster in British Columbia (BC), Canada, contained in the BC Provincial Overdose Cohort. The study sample included persons aged 14 to 74 years on long-term opioid therapy for pain (\u226590 days with \u226590% of days on therapy) between October 2014 and June 2018 (<jats:italic>n<\/jats:italic> = 14,037). At baseline, 7,256 (51.7%) persons were female, the median age was 55 years (quartile 1\u20133: 47\u201363), 227 (1.6%) persons had been diagnosed with OUD (in the past 3 years) and recently (i.e., in the past 90 days) been prescribed OAT, and 483 (3.4%) had been diagnosed with OUD but not recently prescribed OAT. The median follow-up duration per person was 3.7 years (quartile 1\u20133: 2.6\u20134.0). Marginal structural Cox regression with inverse probability of treatment weighting (IPTW) was used to estimate the effect of prescribed opioid treatment for pain status (discontinuation versus tapered therapy versus continued therapy [reference]) on risk of overdose (fatal or nonfatal), stratified by the following groups: people without diagnosed OUD, people with diagnosed OUD receiving OAT, and people with diagnosed OUD not receiving OAT. In marginal structural models with IPTW adjusted for a range of demographic, prescription, comorbidity, and social-structural exposures, discontinuing opioids (i.e., \u22657-day gap[s] in therapy) was associated with increased overdose risk among people without OUD (adjusted hazard ratio [AHR] = 1.44; 95% confidence interval [CI] 1.12, 1.83; <jats:italic>p<\/jats:italic> = 0.004), people with OUD not receiving OAT (AHR = 3.18; 95% CI 1.87, 5.40; <jats:italic>p<\/jats:italic> &lt; 0.001), and people with OUD receiving OAT (AHR = 2.52; 95% CI 1.68, 3.78; <jats:italic>p<\/jats:italic> &lt; 0.001). Opioid tapering (i.e., \u22652 sequential decreases of \u22655% in average daily morphine milligram equivalents) was associated with decreased overdose risk among people with OUD not receiving OAT (AHR = 0.31; 95% CI 0.14, 0.67; <jats:italic>p<\/jats:italic> = 0.003). The main study limitations are that the outcome measure did not capture overdose events that did not result in a healthcare encounter or death, medication dispensation may not reflect medication adherence, residual confounding may have influenced findings, and findings may not be generalizable to persons on opioid therapy in other settings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Discontinuing prescribed opioids was associated with increased overdose risk, particularly among people with OUD. Prescribed opioid tapering was associated with reduced overdose risk among people with OUD not receiving OAT. These findings highlight the need to avoid abrupt discontinuation of opioids for pain. Enhanced guidance is needed to support prescribers in implementing opioid therapy tapering strategies with consideration of OUD and OAT status.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004123","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T19:18:15Z","timestamp":1669922295000},"page":"e1004123","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-2151","authenticated-orcid":true,"given":"Mary Clare","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-4354","authenticated-orcid":true,"given":"Alexis","family":"Crabtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Yin","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-3890","authenticated-orcid":true,"given":"Zishan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Slaunwhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-438X","authenticated-orcid":true,"given":"Lianping","family":"Ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"pmed.1004123.ref001","volume-title":"Opioid-related harms in Canada","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2021"},{"key":"pmed.1004123.ref002","volume-title":"Overdose death rates","author":"National Institute on Drug Abuse","year":"2020"},{"key":"pmed.1004123.ref003","volume-title":"Opioid- and stimulant-related harms in Canada (September 2022)","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2022"},{"key":"pmed.1004123.ref004","unstructured":"BC Gov News. Provincial health officer declares public health emergency. BC Gov News; 2016 Apr 14 [cited 2020 Sep 14]. Available from: https:\/\/news.gov.bc.ca\/releases\/2016HLTH0026-000568."},{"key":"pmed.1004123.ref005","volume-title":"Illicit drug toxicity deaths in BC: January 1, 2012\u2013May 31, 2022","author":"British Columbia Coroners Service","year":"2022"},{"key":"pmed.1004123.ref006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: a rapidly changing risk environment","volume":"46","author":"D. Ciccarone","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1","key":"pmed.1004123.ref007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12889-020-8205-z","article-title":"Correlations between opioid mortality increases related to illicit\/synthetic opioids and reductions of medical opioid dispensing\u2014exploratory analyses from Canada","volume":"20","author":"B Fischer","year":"2020","journal-title":"BMC Public Health"},{"issue":"7","key":"pmed.1004123.ref008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/AJP.0000000000000021","article-title":"The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription","volume":"30","author":"MJ Edlund","year":"2014","journal-title":"Clin J Pain"},{"key":"pmed.1004123.ref009","volume-title":"Opioid prescribing in Canada: how are practices changing?","author":"Canadian Institute for Health Information","year":"2019"},{"issue":"23","key":"pmed.1004123.ref010","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis","volume":"320","author":"JW Busse","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"pmed.1004123.ref011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bph.12634","article-title":"Analgesic efficacy of opioids in chronic pain: recent meta-analyses: opioids in chronic pain","volume":"172","author":"H Reinecke","year":"2015","journal-title":"Br J Pharmacol"},{"key":"pmed.1004123.ref012","unstructured":"College of Physicians and Surgeons of British Columbia. Professional standards and guidelines: safe prescribing of drugs with potential for misuse\/diversion. Vancouver: College of Physicians and Surgeons of British Columbia; 2016 [cited 2022 Nov 7]. Available from: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Publications\/Epid\/Other\/09_CPSBC_Safe_Prescribing_of_Drugs_with_Potential_for_Misuse_Diversion.pdf."},{"key":"pmed.1004123.ref013","volume-title":"The 2017 Canadian guideline for opioids for chronic non-cancer pain","author":"J Busse","year":"2017"},{"key":"pmed.1004123.ref014","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States","volume":"2016","author":"D Dowell","year":"2016","journal-title":"JAMA"},{"key":"pmed.1004123.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugpo.2019.01.015","article-title":"\u201cLike being put on an ice floe and shoved away\u201d: a qualitative study of the impacts of opioid-related policy changes on people who take opioids","volume":"66","author":"T Antoniou","year":"2019","journal-title":"Int J Drug Policy"},{"key":"pmed.1004123.ref016","doi-asserted-by":"crossref","first-page":"m283","DOI":"10.1136\/bmj.m283","article-title":"Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation","volume":"368","author":"EM Oliva","year":"2020","journal-title":"BMJ"},{"issue":"12","key":"pmed.1004123.ref017","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s11606-019-05301-2","article-title":"Mortality after discontinuation of primary care\u2013based chronic opioid therapy for pain: a retrospective cohort study","volume":"34","author":"JR James","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"5","key":"pmed.1004123.ref018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2021.11013","article-title":"Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids","volume":"326","author":"A Agnoli","year":"2021","journal-title":"JAMA"},{"key":"pmed.1004123.ref019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","article-title":"Opioid medication discontinuation and risk of adverse opioid-related health care events","volume":"103","author":"TL Mark","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"pmed.1004123.ref020","doi-asserted-by":"crossref","first-page":"e0232538","DOI":"10.1371\/journal.pone.0232538","article-title":"Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain","volume":"15","author":"PO Coffin","year":"2020","journal-title":"PLoS ONE"},{"key":"pmed.1004123.ref021","doi-asserted-by":"crossref","first-page":"108248","DOI":"10.1016\/j.drugalcdep.2020.108248","article-title":"The association between opioid discontinuation and heroin use: a nested case-control study","volume":"217","author":"IA Binswanger","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"pmed.1004123.ref022","doi-asserted-by":"crossref","first-page":"e192613","DOI":"10.1001\/jamanetworkopen.2019.2613","article-title":"Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy","volume":"2","author":"JM Glanz","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"pmed.1004123.ref023","doi-asserted-by":"crossref","first-page":"e2216726","DOI":"10.1001\/jamanetworkopen.2022.16726","article-title":"Long-term risk of overdose or mental health crisis after opioid dose tapering","volume":"5","author":"JJ Fenton","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"pmed.1004123.ref024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"L Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pmed.1004123.ref025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1155\/2015\/868746","article-title":"Denial of pain medication by health care providers predicts in-hospital illicit drug use among individuals who use illicit drugs","volume":"20","author":"L Ti","year":"2015","journal-title":"Pain Res Manag"},{"issue":"12","key":"pmed.1004123.ref026","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"J Ma","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"4","key":"pmed.1004123.ref027","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/acps.13088","article-title":"Reduction in mortality risk with opioid agonist therapy: a systematic review and meta\u2010analysis","volume":"140","author":"A Bahji","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"pmed.1004123.ref028","doi-asserted-by":"crossref","first-page":"e0210129","DOI":"10.1371\/journal.pone.0210129","article-title":"Development and characteristics of the Provincial Overdose Cohort in British Columbia, Canada","volume":"14","author":"L MacDougall","year":"2019","journal-title":"PLoS ONE"},{"key":"pmed.1004123.ref029","volume-title":"Database PL\/SQL packages and types reference","author":"Oracle","year":"2022"},{"issue":"1","key":"pmed.1004123.ref030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08897077.2020.1748162","article-title":"Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: a retrospective case-control study","volume":"43","author":"K Smolina","year":"2022","journal-title":"Subst Abus"},{"issue":"1","key":"pmed.1004123.ref031","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.9778\/cmajo.20200169","article-title":"Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis","volume":"9","author":"J Moe","year":"2021","journal-title":"CMAJ Open"},{"key":"pmed.1004123.ref032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2018.09.019","article-title":"Patterns and history of prescription drug use among opioid-related drug overdose cases in British Columbia, Canada, 2015\u20132016","volume":"194","author":"K Smolina","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"pmed.1004123.ref033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/add.15580","article-title":"Prevalence of co-occurring mental illness and substance use disorder and association with overdose: a linked data cohort study among residents of British Columbia, Canada","volume":"117","author":"C Keen","year":"2022","journal-title":"Addiction"},{"issue":"11","key":"pmed.1004123.ref034","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care"},{"key":"pmed.1004123.ref035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drugpo.2018.02.001","article-title":"Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets","volume":"55","author":"NZ Janjua","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"5","key":"pmed.1004123.ref036","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"JM Robins","year":"2000","journal-title":"Epidemiology"},{"key":"pmed.1004123.ref037","volume-title":"Illicit drug toxicity type of drug data to May 31, 2022","author":"British Columbia Coroners Service","year":"2022"},{"issue":"34","key":"pmed.1004123.ref038","doi-asserted-by":"crossref","first-page":"E967","DOI":"10.1503\/cmaj.200191","article-title":"Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada","volume":"192","author":"A Crabtree","year":"2020","journal-title":"CMAJ"},{"issue":"8","key":"pmed.1004123.ref039","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1046\/j.1360-0443.2001.96811135.x","article-title":"Heroin overdose: causes and consequences","volume":"96","author":"M Warner-Smith","year":"2001","journal-title":"Addiction"},{"issue":"7","key":"pmed.1004123.ref040","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"JM White","year":"1999","journal-title":"Addiction"},{"issue":"1","key":"pmed.1004123.ref041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pds.4572","article-title":"Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids","volume":"28","author":"JC Young","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pmed.1004123.ref042","doi-asserted-by":"crossref","first-page":"108827","DOI":"10.1016\/j.jsat.2022.108827","article-title":"Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder","volume":"141","author":"LA Lin","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"pmed.1004123.ref043","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M17-0598","article-title":"Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review","volume":"167","author":"JW Frank","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"pmed.1004123.ref044","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jpain.2016.11.003","article-title":"Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial","volume":"18","author":"MD Sullivan","year":"2017","journal-title":"J Pain"},{"issue":"11","key":"pmed.1004123.ref045","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/pm\/pny231","article-title":"Does opioid tapering in chronic pain patients result in improved pain or same pain vs increased pain at taper completion? A structured evidence-based systematic review","volume":"20","author":"DA Fishbain","year":"2019","journal-title":"Pain Med"},{"issue":"5","key":"pmed.1004123.ref046","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2021.11118","article-title":"Opioid tapering practices\u2014time for reconsideration?","volume":"326","author":"M Larochelle","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"pmed.1004123.ref047","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing","volume":"380","author":"D Dowell","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004123.ref048","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1097\/j.pain.0000000000002420","article-title":"Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada","volume":"163","author":"D Martins","year":"2022","journal-title":"Pain"},{"issue":"1","key":"pmed.1004123.ref049","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11606-019-05227-9","article-title":"Opioid taper is associated with subsequent termination of care: a retrospective cohort study","volume":"35","author":"HR Perez","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"4","key":"pmed.1004123.ref050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.amepre.2021.04.019","article-title":"Robust prescription monitoring programs and abrupt discontinuation of long-term opioid use","volume":"61","author":"Y Bao","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"pmed.1004123.ref051","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/10550887.2021.1950262","article-title":"Drug type and risk behaviors associated with non-fatal overdose among people who use drugs: a systematic review and meta-analysis","volume":"40","author":"B Armoon","year":"2022","journal-title":"J Addict Dis"},{"key":"pmed.1004123.ref052","doi-asserted-by":"crossref","first-page":"108127","DOI":"10.1016\/j.drugalcdep.2020.108127","article-title":"Socioeconomic marginalization and opioid-related overdose: a systematic review","volume":"214","author":"J van Draanen","year":"2020","journal-title":"Drug Alcohol Depend"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004213","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T19:18:49Z","timestamp":1669922329000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004123"}},"subtitle":[],"editor":[{"given":"Callam","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004123","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004213","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}